ROCKVILLE, Md., Oct. 19, 2005 (PRIMEZONE) -- Cytomedix, Inc. (AMEX:GTF) chairman and chief executive officer, Kshitij Mohan, Ph. D., will make a presentation at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at 9:25 a.m. Eastern time on Wednesday, November 9, in the Adams Room at the Palace Hotel, 455 Madison Ave. at 51st St., in New York City.
"A key element in the company's growth strategy is developing a base of institutional investors," Dr. Mohan stated. "The Rodman & Renshaw Techvest conference will provide us an excellent platform for gaining exposure with members of the investment community who follow the healthcare industry."
To register for the Cytomedix presentation, please visit www.rodmanandrenshaw.com. Dr. Mohan's presentation will also be available via a live webcast that can be accessed at www.rodmanandrenshaw.com. The webcast will be archived for 90 days.
Rodman & Renshaw LLC, a privately held, New York City full-service investment bank, is the sponsor of the conference. It will include presentations by 290 companies, as well as experts from the medical, scientific and investment communities and will be attended by institutional investors, venture capitalists, company executives, scientists and other industry leaders. To register for the Cytomedix presentation, please visit www.rodmanandrenshaw.com.
About Cytomedix, Inc.
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for uses in the treatment of wounds and other applications. The current offering is the AutoloGel(tm) system, a technology that utilizes an autologous platelet gel composed of multiple growth factors and fibrin matrix. The company has concluded the treatment phase of a blind, prospective, multi-center clinical trial on the use of its technology in healing diabetic foot ulcers. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.
Statements contained in this press release or those that will be made at the healthcare conference, not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including, among others, the success of new sales initiatives; governmental regulation; acceptance by the medical community and competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.